21 CFR Part 11 & RTLS — pharma data integrity.
When RTLS, RFID or sensor telemetry forms part of an electronic record submitted to the FDA — clinical-trial chain of custody, cold-chain excursions, tool-control records — the system falls under 21 CFR Part 11.
The deployment is not blocked, but it must be validated. This is the operator-level summary.
When Part 11 applies, and when it doesn't
Part 11 engages when RTLS data is used to make, modify, maintain, archive, retrieve or transmit electronic records required by predicate FDA regulations (GMP, GLP, GCP). Asset-tracking pumps in a hospital does not engage Part 11.
Logging cold-chain temperature excursions on a clinical-trial shipment does. Tool-control records used to support release of a batch usually do. The right threshold question is: ‘would the FDA expect to see this record in an inspection?’
The four pillars Part 11 requires
A compliant system must produce accurate, complete, attributable and contemporaneous records — the ALCOA principles, extended by ALCOA+.
In practice this means: secure user authentication, tamper-evident audit trails of every record creation and modification, electronic signatures bound to the signed record, system-level access controls, and validated processes for backup, archive and restore.
Most enterprise RTLS platforms support this — but require explicit configuration. Default settings are rarely Part 11-compliant.
Validation — IQ, OQ, PQ
Part 11 systems require formal validation: Installation Qualification (was the system installed as specified?),
Operational Qualification (does it operate per spec under all expected conditions?), and Performance Qualification (does it deliver the documented business outcome reliably over time?).
We produce IQ/OQ/PQ protocols as deliverables in stage 2 (Validate) of the TRACIO Programme Method for any Part 11-scoped deployment.
Audit-readiness — what an inspector will ask
A typical FDA or notified-body audit on an RTLS-enabled record will request: the validated requirements specification, the test execution evidence (IQ/OQ/PQ),
the change-control history of every configuration change, user-access logs, the SOP for ongoing operation, and evidence of training.
We assemble the audit pack as a stage 3 (Deploy) deliverable, with version-controlled release into the QMS.
Frequently asked questions
Are commercial RTLS platforms inherently Part 11-compliant?
No — they support Part 11 compliance with appropriate configuration and validation. The platform is one piece of a compliant system; the validation, SOPs and audit trail design are equally important.
Vendor marketing claims of ‘Part 11 compliant’ usually mean ‘capable of being configured for compliance’ — verify in pilot.
Who owns validation — TRACIO, your QA team, or the vendor?
Validation is jointly owned. We produce the protocols and execute them with your QA team; vendor support is needed for system-specific evidence. Ownership of the final validated state sits with your QA function, not with us — that's a non-negotiable principle of GxP.
How does the deployment cope with system updates and patches?
Through formal change control. Every patch is risk-assessed; high-impact patches trigger re-validation of affected functions; low-impact patches are documented but don't require full re-validation. We design the change-control SOP as a stage 3 deliverable.
What's the typical timeline for a Part 11-validated RTLS deployment?
Add 8-16 weeks to a non-validated equivalent to cover protocol authoring, execution and QA approval. The right-sizing of validation effort is determined by GxP risk classification at gate 1.
Last updated: